Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2011

View Archived Issues

Preclinical and clinical phase I/II data presented on GSK-573719 for COPD

Novel SMYD2 inhibitor identified at AstraZeneca

Novel pan-Aurora kinase inhibitor is active against drug-resistant cancer cells

Novel CO-releasing rhenium complexes developed at Swiss university

Phosphagenics to advance development of twice-weekly oxycodone patch

Enrollment complete in pediatric Xerecept trial

Incozen Therapeutics describes new PI3K-delta inhibitor

Creabilis raises funds for development of CT-327

Scientists at GSK prepare new lysophospholipid S1P1 receptor agonists

Novel neuroprotective agents patented

New saRNA molecules claimed by University of California scientists

Novel PP1 inhibitors synthesized

EntreMed reports encouraging phase II results on ENMD-2076

Fibrocell Science launches laViv in U.S.

InSite Vision releases phase II pharmacokinetic data on BromSite

Intellect Neurosciences and ViroPharma enter licensing agreement for OX-1

CalciMedica presents novel protein orai-1 inhibitors

NuPathe reports encouraging data from migraine patch trial

Gliknik receives SBIR contract to advance stradobodies

Merck Serono and Ono Pharmaceutical collaborate on MS drug and cancer vaccine

G-Zero Therapeutics receives NIH grant for studies in radiation exposure

Karo Bio enrolls first patient in AKKA study

Neurocrine and Abbott reach second milestone in elagolix collaboration

First patients dosed with Xiaflex in Dupuytren's contracture multicord study

Cariprazine study meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...